--- mi_id: MIPR-node_9b3282d type: press_release canonical_url: "https://www.pheonixresearch.com/healthcare/healthcare-pharmaceuticals/press-release/phycedelic-drugs-market/" md_url: "https://www.pheonixresearch.com/healthcare/healthcare-pharmaceuticals/press-release/phycedelic-drugs-market.md" schema: "@type": NewsArticle "@id": MIPR-node_9b3282d url: "https://www.pheonixresearch.com/healthcare/healthcare-pharmaceuticals/press-release/phycedelic-drugs-market/" title: Pheonix Research Publishes 2026 “Global Psychedelic Drugs Market Outlook – Press Release” description: "The Global Psychedelic Drugs Market is projected to grow from USD 4.85 Billion in 2025 to USD 14.60 Billion by 2033, at a CAGR of 14.80%." datePublished: "2025-09-13T09:13:48+00:00" dateModified: "2026-06-27T06:18:05+00:00" keywords: - Global Psychedelic Drugs Market - Psychedelic Drugs Market Size - Psychedelic Drugs Market Share - Psychedelic Drugs Market Growth - Psychedelic Drugs Industry Analysis - Psychedelic Drugs Market Forecast 2033 - Psilocybin Market - MDMA-Assisted Therapy Market - Ketamine Therapy Market - Mental Health Therapeutics Market - Psychedelic-Assisted Therapy Market - Depression Treatment Market - PTSD Treatment Market - Neuroscience Market - Precision Psychiatry Market - Pharmaceutical Biotechnology Market - Clinical Research Market - Mental Healthcare Market - Psychedelic Drug Industry Trends - Global Psychedelic Drugs Industry Report 2026-2033 isPartOf: - id: MISG-node_a5546f7 type: CollectionPage url: "https://www.pheonixresearch.com/healthcare/healthcare-pharmaceuticals/" name: "healthcare & pharmaceuticals" - id: MIIN-node_50b4dbf type: CollectionPage url: "https://www.pheonixresearch.com/healthcare/" name: Healthcare - id: MIWS-root type: WebSite url: "https://www.pheonixresearch.com/" name: Pheonix Research acf: phoenix_meta_title: "Global Psychedelic Drugs Market Size, Share & Forecast Report" phoenix_meta_description: "The Global Psychedelic Drugs Market is projected to grow from USD 4.85 Billion in 2025 to USD 14.60 Billion by 2033, at a CAGR of 14.80%. " global_schema: organization: "@id": MIWS-root#organization "@type": Organization url: "https://www.pheonixresearch.com/" name: Pheonix Research website: "@id": MIWS-root "@type": WebSite url: "https://www.pheonixresearch.com/" name: Pheonix Research api: "@id": MIWS-root#api "@type": WebAPI url: "https://www.pheonixresearch.com/" graph: node_id: MIPR-node_9b3282d graph_node_endpoint: "https://graph.statsfocus.com/api/v1/query/live/node/MIPR-node_9b3282d" graph_snapshot: "https://graph.statsfocus.com/api/v1/read/live/graph" graph_exclusions: "https://graph.statsfocus.com/api/v1/read/live/exclusions" graph_meta: "https://graph.statsfocus.com/api/v1/read/live/meta" graph_bundle: "https://graph.statsfocus.com/api/v1/read/live/bundle" discovery: discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json" llms_txt: "https://www.pheonixresearch.com/llms.txt" sitemap: "https://www.pheonixresearch.com/sitemap.xml" --- # Pheonix Research Publishes 2026 “Global Psychedelic Drugs Market Outlook – Press Release” Global Psychedelic Drugs Market to Reach USD 14.60 Billion by 2033 Amid Expanding Clinical Research, Rising Mental Health Needs & Advancing Psychedelic-Assisted Therapies June 2026 | Pheonix Market Research The Global Psychedelic Drugs Market is projected to grow from USD 4.85 Billion in 2025 to approximately USD 14.60 Billion by 2033, registering a CAGR of 14.80% during the forecast period of 2026–2033, according to the latest market intelligence report published by Pheonix Market Research. The market is witnessing significant growth driven by increasing investments in mental health research, expanding clinical trials evaluating psychedelic-assisted therapies, growing awareness of treatment-resistant psychiatric disorders, and continuous advancements in neuroscience. Pharmaceutical companies, biotechnology firms, academic institutions, and healthcare organizations are increasingly collaborating to accelerate the development of innovative therapies targeting depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance use disorders, and other complex mental health conditions. The industry is also benefiting from growing clinical evidence supporting psychedelic-assisted psychotherapy, rising investments in precision mental healthcare, and expanding drug development pipelines focused on novel psychedelic compounds. Advancements in personalized treatment approaches, standardized therapeutic protocols, and regulatory progress in selected regions are further strengthening market expansion. In addition, increasing demand for innovative mental health solutions is encouraging continued investment in research, development, and specialized treatment infrastructure. According to Pheonix Market Research, ongoing advancements in neuroscience, expanding clinical research programs, and evolving regulatory pathways for innovative psychiatric therapies are expected to create significant growth opportunities throughout the forecast period. Asia-Pacific is anticipated to emerge as the fastest-growing regional market due to increasing healthcare investments, expanding pharmaceutical research activities, and growing awareness of mental health disorders. North America continues to dominate the global market owing to its strong biotechnology ecosystem, extensive clinical research activities, favorable investment environment, and evolving regulatory frameworks supporting innovative mental health treatments. A Senior Healthcare & Life Sciences Analyst at Pheonix Market Research stated: “Psychedelic-assisted therapies are emerging as a promising area of mental healthcare innovation, supported by expanding clinical research and growing scientific understanding of their therapeutic potential. As regulatory pathways continue to evolve and evidence from clinical studies strengthens, these therapies are expected to play an increasingly important role in addressing unmet mental health needs worldwide.” Key Market Highlights Psilocybin-Based Therapies remain the largest segment due to extensive clinical research targeting depression and other psychiatric disorders. MDMA-Assisted Therapy is the fastest-growing segment driven by expanding clinical studies for PTSD and trauma-related conditions. Hospitals & Specialty Mental Health Clinics continue to represent the leading end-use segment globally. Clinical research expansion is accelerating innovation in psychedelic-assisted psychotherapy. Precision mental healthcare approaches are supporting personalized psychiatric treatment strategies. Increasing investments in neuroscience and pharmaceutical R&D are strengthening product development pipelines. Clinical trial regulations, controlled substance policies, and mental health treatment guidelines continue to shape industry growth. Report Highlights Market Size (2025): USD 4.85 Billion Market Size (2033): USD 14.60 Billion CAGR (2026–2033): 14.80% Largest Segment: Psilocybin-Based Therapies Fastest Growing Segment: MDMA-Assisted Therapy Leading End-Use Segment: Hospitals & Specialty Mental Health Clinics Key Trend: Clinical Research Expansion, Psychedelic-Assisted Psychotherapy & Precision Mental Healthcare About Pheonix Market Research Pheonix Market Research is a global market intelligence and strategic advisory firm specializing in pharmaceuticals, biotechnology, healthcare, life sciences, and emerging medical technologies. The firm provides data-driven insights, market forecasting, competitive intelligence, and strategic recommendations that enable businesses, investors, and policymakers to make informed decisions in rapidly evolving healthcare markets. 📊 For detailed insights and full report access:Website: https://www.pheonixresearch.com/healthcare/healthcare-pharmaceuticals/market-report/global-phycedelic-drugs-market/ Media Contact Pheonix Market ResearchEmail: media@pheonixmarketresearch.comWebsite: www.pheonixmarketresearch.com